Skip to main content

TNF inhibitor

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article

GI Perforations with Tocilizumab Greater than Other Biologics

Jul 27, 2020

A study from a Swedish population shows the real-world risk of gastrointestinal (GI) perforations in rheumatoid arthritis (RA) patients taking biologics finds that the risk was greatest in RA patients taking tocilizumab (TCZ), compared with RA patient taking tumour necrosis factor inhibitors (

Read Article

Risankizumab Outduels Secukinumab in Psoriasis

Jul 20, 2020

The IMMerge trial has demonstrated the superiority of interleukin (IL)‐23 over IL-17A inhibition adults with plaque psoriasis.



This multicenter, phase 3, open‐label study enrolled 327 adult patients with chronic, moderate‐to‐severe plaque psoriasis who were randomised risankizumab (

Read Article
Single center retrospective Korean study of 1280 Ankylosing Spondylitis patients (595 exposed to TNFi) showed that TNFi was associated with significantly decreased Xray change rate (mSASSS) (β=−0.112, p=0.004). https://t.co/W4j0Ckt0R2

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2020

JAK Inhibitor Succeeds as Monotherapy in Rheumatoid Arthritis

Jul 14, 2020

The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) given as monotherapy was more effective than methotrexate alone in methotrexate-naive patients with active rheumatoid arthritis (RA) in a multinational phase III trial.

Read Article

IL-17 Superior to TNF Inhibition in Psoriatic Arthritis

Jul 14, 2020

A one year head-to-head (H2H) trial has shown ixekizumab (IXE) to be superior to adalimumab (ADA) in psoriatic arthritis (PsA); for both skin and articular outcomes.

The SPIRIT H2H study was a 52-week trial of 566 biologic DMARD naive, PsA patients, randomized to received either IXE or ADA. The

Read Article
Study of 1362 #RA patients given TNF inhibitors, abatacept, tocilizumab between 2011-17 finds TCZ had best survival regardless of age; ABA had lowest D/C for adverse events & disease activity improved more with TNFi. https://t.co/7RRO9M4Wf0

Dr. John Cush RheumNow ( View Tweet)

Jun 26, 2020
TNFi, ABA, TCZ Retention rates looked at in 1362 RA according to age. For < 65 years, 3-year retention was best for TCZ 69%. For pts 65–74 years, retention rates highest for TCZ . For ≥ 75 years, 3-year retention rates best for ABA & TCZ (63% & 58%).

Dr. John Cush RheumNow ( View Tweet)

Jun 24, 2020

Adverse Events With Rheum Biologics Rise With Age

Jun 23, 2020

Among patients with rheumatic diseases, age and female sex were important factors associated with the development of a first adverse event after initiating biologic treatment, Spanish researchers reported.

Read Article

RheumNow Podcast – Enough Already with Weaning (6.19.20)

Jun 19, 2020

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article

Virtual EULAR 2020 Round Up

Jun 12, 2020

In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic

Read Article

Day 4 - Top 3 from EULAR 2020

Jun 11, 2020

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article

Day 3 - Top 5 from EULAR 2020

Jun 10, 2020

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article
Lots of talk about best bDMARDs in RA-ILD, but what about in RA-assoc bronchiectasis? @Yuz6Yusof found rituximab had better 'lung survival' vs TNFi (similar baseline stats) Something to consider in these difficult-to-treat pts? @LeedsBRC Newcastle THU0143 #EULAR2020 @RheumNow
David Liew drdavidliew ( View Tweet)
Jun 07, 2020
#EULAR2020 Dr. V Ritschl:EULAR Task Force on Patient Adherance: 30-80% of pts do not adhere to Rx. resulting in ⬆️dz severity, pain, fatigue, depression, decreased in function, physical activity. HCPs should discuss adherance reg. & explore factors affecting adherance. @RheumNow
Jun 07, 2020
ENbrel works in long term for the few people left on the drug at 10 yrs with SpA. Enormous dropout. If you are still on Rx for a decade you are in the minority.

Janet Pope Janetbirdope ( View Tweet)

Jun 07, 2020
Study in Norway reveals that the majority of the women w/ SpA were not treated with TNF inhibitors before or during pregnancy. Few on TNFi were continued on tx during pregnancy.
Dr. Rachel Tate uptoTate ( View Tweet)
Jun 06, 2020
Switching TNFi to VDZ in pts IBD-related SpA associated w/ articular exacerbation of SpA in 1 out of 4 patients within the first 5 months. New-onset MEM is also observed in up to 15% of patients with IBD treated with VDZ.
Dr. Rachel Tate uptoTate ( View Tweet)
Jun 06, 2020
#EULAR2020 Recc for irAEs w/ICI: 1. GC's ok, goal<10 mg/d, any csDMARD, bDMARD (TNFi/IL-6),🚫ABT xcept life-threatening myositis 2. Myositis beware bulbar signs: dysphagia, dysarthria, dysphonia: stop ICIs,⬆️GC, IVIG/PE 3.
Jun 06, 2020
Don’t forget significant fibrosis with ILD has +RCT with nintedanib INBUILD study. Lots of buzz of RA ILD where MTX is OK, TNFi may have more ILD than other bDMARDs, biomatkers KL-6 @eular_org OP0038 #EULAR2020 @CRASCRRheum https://t.co/OihF3LmNYQ
Janet Pope Janetbirdope ( View Tweet)
Jun 06, 2020
Can we predict which RA pts will have secondary failure to TNFi in advance? B-cell activating factor (BAFF) may play a role, and in age >54, pre-TNFi BAFF levels predict anti-drug Ab. A potential step toward better drug survival?
David Liew drdavidliew ( View Tweet)
Jun 06, 2020
#EULAR2020 OP0019 DON'T STOP TNFi in RA remission per ARCTIC-REWIND trial: RCT X 1 year n=99 multicenter gov't funded- DAS28 remission X1 year, dz X10 yrs, 2/3 pts (RF+/CCP+), no doppler signal. Results: 63% flared who had TNFi w/drawn vs.
Jun 06, 2020
Do certain TNFi get more affected by obesity in RA?
David Liew drdavidliew ( View Tweet)
Jun 05, 2020
And another one! No association of MTX with worsening of ILD in this study by Men-Vazquez et al. #EULAR2020 https://t.co/X7C6KyC29L
Richard Conway RichardPAConway ( View Tweet)
Jun 05, 2020
Another Italian COVID-19 dermatology report: 1,193 skin psoriasis patients on TNFi, IL17,IL23,IL12/23 & apremilast: 22 patients infected, of those 5 hospitalised, none died https://t.co/HpN908qsHd

Dr Philip Robinson philipcrobinson ( View Tweet)

Jun 05, 2020
×